Evidence map›Paper›PMID 19077666›Full record

ArticlePharmacogenetics and genomics2009

Twenty-one-base-pair insertion polymorphism creates an enhancer element and potentiates SLC6A1 GABA transporter promoter activity.

Rungnapa Hirunsatit, Elizabeth D George, Barbara K Lipska, Hani M Elwafi, Lisa Sander, Carolyn M Yrigollen, Joel Gelernter, Elena L Grigorenko, Jaakko Lappalainen, Shrikant Mane and 3 more

Open access · greenAbstract read
In one paragraph

Article in Pharmacogenetics and genomics, 2009. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 16 papers.

0numbers the graph read from it
0cells of the map it votes in
16citing papers in PubMed
0.6field-weighted citation impact, top 40% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

16 citing papers in PubMed, 35 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. Article
  5. Article
  6. Article
  7. Article
  8. Article
  9. Article
  10. Article
  11. Article
  12. Review
  13. Review
  14. Review
  15. Article
  16. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

13 authors at 6 institutions in 3 countries.

Rungnapa HirunsatitDepartment of Psychiatry and the Yale Keck Center, Yale University School of Medicine, New Haven, CT 06511-6624, USA.
Elizabeth D George
Barbara K Lipska
Hani M Elwafi
Lisa Sander
Carolyn M Yrigollen
Joel Gelernter
Elena L Grigorenko
Jaakko Lappalainen
Shrikant Mane
Angus C Nairn
Joel E Kleinman
Arthur A Simen
AstraZeneca (United States) · USChild Development Center · QANational Institute of Mental Health · USVA Connecticut Healthcare System · USYale Cancer Center · USYale University · US

Funding

Procurement and Characterization of Postmortem Brain TissueZICMH002903 · NIMH · NATIONAL INSTITUTE OF MENTAL HEALTH · PI MARENCO, STEFANO · 2009 to 2025
$56.0M
Yale/NIDA Neuroproteomics Research CenterP30DA018343 · NIDA · YALE UNIVERSITY · PI Marina R Picciotto · 2004 to 2026
$37.1M
Postmortem Brain Tissue Examination in Neuropsychiatric DisordersZIAMH002399 · NIMH · NATIONAL INSTITUTE OF MENTAL HEALTH · PI AMARA, SUSAN · 2009 to 2014
$11.9M
RESEARCH TRAINING - BIOLOGICAL SCIENCEST32MH014276 · NIMH · YALE UNIVERSITY · PI Marina R Picciotto · 1985 to 2026
$7.2M
Yale Microarray Center for Research the Nervous SystemU24NS051869 · NINDS · YALE UNIVERSITY · PI MANE, SHRIKANT M · 2005 to 2009
$6.9M
Yale University Clinical and Translational Science Award ProgramKL2RR024138 · NCRR · YALE UNIVERSITY · PI SHERWIN, ROBERT S · 2006 to 2011
$4.8M
Neurobiological Foundations of reading (dis)abilityR01HD048830 · NICHD · YALE UNIVERSITY · PI PUGH, KENNETH R. · 2005 to 2010
$3.0M
Thai-US Drug Dependence Genetics Research Training GrantD43TW006166 · FIC · YALE UNIVERSITY · PI GELERNTER, JOEL · 2002 to 2006
$1.7M
YALE BIOMEDICAL SUPERCOMPUTER: NEUROSCIENCES10RR019895 · NCRR · YALE UNIVERSITY · PI WILLIAMS, KENNETH ROBERT · 2004 to 2004
$1.6M
Epidemiological Survey of Learning Disabilities in ZambiaR21TW006764 · FIC · YALE UNIVERSITY · PI GRIGORENKO, ELENA L · 2003 to 2005
$331k
FIC NIH HHS D43 TW006166FIC NIH HHS D43 TW 06166FIC NIH HHS R21 TW006764FIC NIH HHS TW006764NCRR NIH HHS 1 KL2 RR 024138NCRR NIH HHS KL2 RR024138NCRR NIH HHS RR 19895NCRR NIH HHS S10 RR019895NICHD NIH HHS HD048830NICHD NIH HHS R01 HD048830NIDA NIH HHS DA 018343NIDA NIH HHS P30 DA018343NIMH NIH HHS T32 MH014276NIMH NIH HHS T32-MH14276NINDS NIH HHS U24 NS051869
6 · The paper itself

Abstract

objectiveSodium-dependent and chloride-dependent gamma-aminobutyric acid (GABA) transporter 1 (SLC6A1) is the target of a number of drugs of clinical importance and is a major determinant of synaptic GABA concentrations. We resequenced the human SLC6A1 gene previously and discovered a novel 21 bp insertion in the predicted promoter region that creates a second tandem copy of the sequence. Here we sought to determine the functional relevance of this variation.

methodsWe used reporter assays, mobility shift assays, quantitative PCR, and proteomics methods as well as postmortem expression analysis for this work.

resultsReporter assays showed that the insertion allele significantly increases promoter activity in multiple cell lines. The zinc finger transcription factor ZNF148 was found to significantly transactivate the promoter and increase expression when overexpressed but could not account for the differences in activity between the two alleles of the promoter. Copy number of the insertion sequence was associated with exponentially increasing activity of a downstream promoter, suggesting that the insertion sequence has enhancer activity when present in multiple copies. SLC6A1 promoter genotype was found to predict SLC6A1 RNA expression in human postmortem hippocampal samples. These results suggest that the insertion polymorphism leads to increased SLC6A1 promoter activity because, in part, of creation of an enhancer element when present as multiple copies. Genotyping individuals from Tanzania in this study suggested that the insertion allele has its origin in Africa.

conclusionOn account of the effect of the insertion on promoter activity, this relatively common polymorphism may prove useful in predicting clinical response to pharmacological modulators of SLC6A1 as well as GABAergic function in individuals of African descent.

Indexed as

Mutagenesis, InsertionalAdolescentAdultAgedAnimalsBase SequenceBlack or African AmericanCase-Control StudiesCell LineDNA PrimersEnhancer Elements, GeneticFemaleGABA Plasma Membrane Transport ProteinsGene ExpressionHippocampusHumansDNA PrimersGABA Plasma Membrane Transport ProteinsRecombinant ProteinsRNA, MessengerSLC6A1 protein, human

Identifiers

PMID19077666
PMCPMC2791799
OpenAlexW2031580726

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.